Search results for "From ACP Journal Club"
Weekly efsitora compared to degludec in type 1 and type 2 diabetes by industry studies
Although two manufacturer trials showed that the weekly insulin efsitora was noninferior to daily degludec, that finding might not be sufficient to justify its use, particularly in patients with type 1 diabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2025/01/10/6.htm
10 Jan 2025
In T2D, SGLT-2 inhibitor effects on CV and kidney outcomes were consistent regardless of GLP-1 receptor agonist use
The number of patients who received combination therapy with an SGLT-2 inhibitor and a GLP-1 receptor agonist in a recent review was too small to guide practice, but it's likely that more patients will soon be on this regimen, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/11/08/7.htm
8 Nov 2024
In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y
A recent industry-funded trial solidifies glucagon-like peptide-1 receptor agonists as a treatment for patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD), but questions about safety in patients with advanced CKD remain, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/09/13/8.htm
13 Sep 2024
In patients with type 2 diabetes and recent MI, colchicine reduced a composite CV outcome at 23 mo
Based on this and previous trials, low-dose colchicine should be considered as anti-inflammatory therapy for secondary prevention after myocardial infarction (MI) in patients at high risk for cardiovascular (CV) events, according to an ACP Journal Club commentary.
https://diabetes.acponline.org/archives/2024/05/10/7.htm
10 May 2024
In HF, T2D, CKD, or atherosclerotic CVD, SGLT-2 inhibitors reduce HF hospitalizations and CV mortality
Recent research on newer classes of diabetes drugs indicates that dysglycemia may not be a prerequisite to benefit from their cardiovascular and renal benefits, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/11/08/6.htm
8 Nov 2024
After COVID-19 diagnosis, risk for incident type 2 diabetes was elevated for up to 2 y
Given that this large study found an elevated incidence of type 2 diabetes up to two years after infection, COVID-19 could now be characterized as a possible risk factor for diabetes, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/12/13/9.htm
13 Dec 2024
In adults with metabolic dysfunction, the MAF-5 score predicted risk for liver fibrosis (AUC range, 0.73 to 0.81)
The new Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) score could potentially identify patients in primary care who are at risk for progressive fibrosis and facilitate interventions and treatment, but it needs to be prospectively validated, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/10/11/6.htm
11 Oct 2024
In type 2 diabetes, the effectiveness and side effects of GLP-1 RAs vary
A recent systematic review of the beneficial and harmful effects of 15 glucagon-like peptide-1 receptor agonists (GLP-1 RAs) should be helpful to clinicians and suggests which drugs are likely to dominate the market in the next few years, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/05/10/8.htm
10 May 2024
In T1DM without CVD, the LIFE-T1D model predicted lifetime risk for CVD and non-CVD mortality
The most important implication of this new model for predicting cardiovascular disease (CVD) risk among patients with type 1 diabetes (T1DM) may be that it will motivate clinicians to initiate statin therapy in younger patients, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2024/07/12/6.htm
12 Jul 2024
KDIGO provided recommendations on SGLT2 inhibitors and nonsteroidal MRAs in patients with diabetes and CKD
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
https://diabetes.acponline.org/archives/2023/05/12/7.htm
12 May 2023